On January 3, 2018 Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, reported that David Kalergis, Chairman and Chief Executive Officer, will present an overview of the Company and recent advancements of its lead product candidate, trans sodium crocetinate (TSC), at the 10th Annual Biotech Showcase Conference to be held on January 8–10, 2018 at the Hilton San Francisco Union Square Hotel (Press release, Diffusion Pharmaceuticals, JAN 3, 2018, View Source [SID1234522840]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Kalergis is scheduled to present on Monday, January 8, 2018 at 2:30 p.m. Pacific time.

The presentation will be webcast live and available only during the time of the Company’s live presentation. To access the live webcast, investors may visit the investor relations section of Diffusion Pharmaceuticals website at www.diffusionpharma.com.